Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCAR- F33S cells

Cell therapy · Kills target cells · developed by Nanjing Legend Biotech

N/A Most advanced trial
LEGN Developer
1 Registered trials

What is LCAR- F33S cells?

LCAR-F33S is a cell therapy given after a conditioning regimen of cyclophosphamide and fludarabine, studied in relapsed or refractory multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Kills target cells
Therapy area
Oncology
Developer
Nanjing Legend Biotech Co. (LEGN)
FDA status
Investigational, not approved in the US. Most advanced trial: N/A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07100067 N/A Relapsed/Refractory Multiple Myeloma(MM) Recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Multiple Myeloma(MM)

More from Nanjing Legend Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.

Follow LEGN, the company behind LCAR- F33S cells

See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.